Activity from announced rounds
Boehringer Ingelheim Venture Fund is a corporate venture investment operation identified in Cloverleaf Bio and Brainomix financing histories.
Cloverleaf develops engineered transfer-RNA therapies intended to inhibit cancer cells’ RNA-modifying enzymes. Brainomix develops AI imaging tools for stroke and lung fibrosis. The announcements connect the venture operation to both experimental therapeutics and clinical image analysis.
Cloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical.